secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001628280-24-037051
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025
--------------------------------------------------------------------------------

- Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.
- Cash, cash equivalents, restricted cash and marketable securities of $78.1M as of June 30, 2024.
- Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo; top-line results expected mid-2025.
- Phase 1a SAD/MAD trial of VYN202 ongoing; SAD data in Q3 2024, MAD data in Q4 2024.
- Appointed Dr. Subhashis Banerjee as SVP of Clinical Development; previously at Bristol Myers Squibb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828024037051/0001628280-24-037051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828024037051/mnlo-20240814.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-037051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer